Search Tag: Radiopharmaceutical Therapy
2024 01 Oct
Metastatic castration-resistant prostate cancer (mCRPC) represents a highly challenging stage of prostate cancer, often characterised by heterogeneous tumour behaviour across different metastases. This complexity, referred to as intrapatient intermetastatic heterogeneity (IIH), can significantly affect treatment outcomes. Recent advances in molecular...Read more